Enlivex Therapeutics Ltd.

Enlivex Ltd. (formerly Enlivex Therapeutics Ltd., Nasdaq: ENLV), founded in 2005 and headquartered in Ness Ziona, Israel, is a clinical-stage macrophage reprogramming immunotherapy company focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to restore macrophages to their homeostatic state for the treatment of inflammatory diseases. The company's lead programs include Allocetra™ in a Phase II clinical trial for organ dysfunction and failure caused by sepsis, as well as a Phase I/II trial targeting moderate knee osteoarthritis, with additional investigations into osteoarthritis of the temporomandibular joint (TMJ) and solid tumors. In February 2026, the company rebranded to Enlivex Ltd. and adopted a dual strategy that combines its core clinical immunotherapy development with a prediction markets treasury model built around the Rain decentralized prediction markets protocol on Arbitrum. Trading on the NASDAQ Capital Market with a market capitalization of approximately $14.8 million, Enlivex remains an early-stage company with no product revenues, continuing to advance its innovative macrophage-modulating platform targeting significant unmet medical needs across multiple high-value therapeutic areas.